Group 1 - The core viewpoint of the news is that Hualan Co., Ltd. has seen a significant stock price increase of 5.18%, reaching 39.00 yuan per share, with a trading volume of 260 million yuan and a turnover rate of 4.34%, resulting in a total market capitalization of 6.404 billion yuan [1] - Hualan Co., Ltd. specializes in the research, production, and sales of packaging materials for injectable drugs, with its main business revenue composition being 49.07% from film-coated rubber stoppers, 48.50% from conventional rubber stoppers, and 2.43% from other products [1] Group 2 - From the perspective of fund holdings, Dachen Fund has a significant position in Hualan Co., Ltd., with its Dachen Growth Mixed Fund holding 620,000 shares, accounting for 3.29% of the fund's net value, making it the eighth largest holding [2] - The Dachen Growth Mixed Fund has achieved a year-to-date return of 25.08% and a one-year return of 45.68%, ranking 3502 out of 8172 and 3660 out of 7980 respectively in its category [2] - The fund manager, Zou Jian, has been in position for 4 years and 236 days, with the fund's total asset size being 1.086 billion yuan, and the best and worst returns during his tenure being 13.52% and -21.29% respectively [2]

证券代码：301093 证券简称：华兰股份 公告编号：2025-093 江苏华兰药用新材料股份有限公司 2025 年第四次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、 本次股东会未出现否决议案的情形。 一、 会议召开和出席情况 （一） 会议召开时间 通过深圳证券交易所交易系统进行网络投票的时间为：2025 年 9 月 15 日 （星期一）9:15-9:25，9:30-11:30 和 13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 9 月 15 日（星期一）9:15-15:00。 （二） 现场会议召开地点：江苏省江阴市申港镇镇澄路 1488 号江苏华兰 药用新材料股份有限公司会议室。 2、 本次股东会未涉及变更以往股东会已通过的决议。 3、 本次股东会审议各项议案均对中小股东的表决单独计票。 1、 现场会议召开时间：2025 年 9 月 15 日（星期一）下午 14:30 2、 网络投票时间：2025 年 9 月 15 日（星期一） （三） 会议召开方式：采取现场投票与网络投票相结 ...

北京植德（上海）律师事务所 关于江苏华兰药用新材料股份有限公司 2025 年第四次临时股东会的 法律意见书 植德沪(会)字[2025]0042 号 二〇二五年九月 上海市徐汇区虹桥路 183 号徐家汇中心三期 A 座办公楼 27 层 邮编：200030 27th Floor Tower A, THREE itc, No.183 Hongqiao Road, Xuhui District, Shanghai 200030 P.R.C 电话(Tel)：021-52533500 传真(Fax)：021-52533599 www.meritsandtree.com 北京植德（上海）律师事务所 关于江苏华兰药用新材料股份有限公司 2025年第四次临时股东会的 法律意见书 植德沪(会)字[2025]0042号 致：江苏华兰药用新材料股份有限公司 北京植德（上海）律师事务所（以下简称"本所"）接受江苏华兰药用新材 料股份有限公司（以下简称"公司"或"华兰股份"）的委托，指派律师出席并 见证公司2025年第四次临时股东会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共 ...

Group 1 - The core point of the article is that Hualan Co., Ltd. has established a wholly-owned subsidiary in Nanjing with an investment of 5 million RMB [1] - The newly established subsidiary will be included in the company's consolidated financial statements [1] - The subsidiary has completed the business registration process and obtained a business license from the Nanjing Qinhuai District Administrative Service Management Office [1]

本次对外投资是公司战略布局和产业发展的需要，有利于发展公司新的业务增长点，扩大影响力，促进 公司健康发展。南京仁青眠曲健康科技有限公司成立后，将纳入公司合并报表范围。 智通财经APP讯，华兰股份(301093.SZ)发布公告，为满足公司战略布局和产业发展的需要，公司控股子 公司西藏华兰藏医药科技有限公司以自有资金人民币500万元在南京设立全资子公司(即华兰股份南京孙 公司)。该南京孙公司成立后，将纳入公司合并报表范围。近日，南京孙公司已完成工商注册登记手 续，并取得南京市秦淮区政务服务管理办公室颁发的《营业执照》。 ...

华兰股份（301093）(301093.SZ)发布公告，为满足公司战略布局和产业发展的需要，公司控股子公司 西藏华兰藏医药科技有限公司以自有资金人民币500万元在南京设立全资子公司(即华兰股份南京孙公 司)。该南京孙公司成立后，将纳入公司合并报表范围。近日，南京孙公司已完成工商注册登记手续， 并取得南京市秦淮区政务服务管理办公室颁发的《营业执照》。 本次对外投资是公司战略布局和产业发展的需要，有利于发展公司新的业务增长点，扩大影响力，促进 公司健康发展。南京仁青眠曲健康科技有限公司成立后，将纳入公司合并报表范围。 ...

江苏华兰药用新材料股份有限公司 关于设立南京孙公司并完成工商登记的公告 证券代码：301093 证券简称：华兰股份 公告编号：2025-092 | 一般项目：技术服务、技术开发、技术咨询、技术交流、技术转让、技 | 术推广；健康咨询服务（不含诊疗服务）；医学研究和试验发展；医学 | | | --- | --- | --- | | 研究和试验发展（除人体干细胞、基因诊断与治疗技术开发和应用）； | 化妆品零售；日用百货销售；个人卫生用品销售；卫生用品和一次性使 | | | 用医疗用品销售；美发饰品销售；日用杂品销售；养生保健服务（非医 | 疗）；保健食品（预包装）销售（除依法须经批准的项目外，凭营业执 | | | 照依法自主开展经营活动） | 西藏华兰藏医药科技有限公司持有其 | 100%股份，公司间接持有其 | | 股权结构 | 61.40%股份。 | | 三、 对外投资的目的和对公司的影响 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 对外投资概述 为满足江苏华兰药用新材料股份有限公司（以下简称"公司"或"华兰股 份"）战略布局和产业发展的需要，公司 ...

Group 1 - The core point of the news is that Hualan Co., Ltd. experienced a 5.25% drop in stock price, closing at 33.38 yuan per share, with a trading volume of 208 million yuan and a turnover rate of 3.84%, resulting in a total market capitalization of 5.481 billion yuan [1] - Hualan Co., Ltd. is based in Jiangyin City, Jiangsu Province, and was established on June 4, 1992, with its listing date on November 1, 2021. The company specializes in the research, production, and sales of packaging materials for injectable drugs [1] - The main business revenue composition of Hualan Co., Ltd. includes 49.07% from film-coated rubber stoppers, 48.50% from conventional rubber stoppers, and 2.43% from other products [1] Group 2 - From the perspective of major fund holdings, one fund under Galaxy Fund has a significant position in Hualan Co., Ltd. The Galaxy Kangle Stock A fund (519673) reduced its holdings by 22,800 shares in the second quarter, now holding 355,900 shares, which accounts for 6.37% of the fund's net value, making it the largest holding [2] - The Galaxy Kangle Stock A fund was established on November 18, 2014, with a latest scale of 155 million yuan. Year-to-date returns are 30.98%, ranking 1067 out of 4222 in its category; the one-year return is 56.28%, ranking 1381 out of 3789; and since inception, the return is 172.7% [2] - The fund manager of Galaxy Kangle Stock A is Fang Wei, who has been in the position for 4 years and 119 days, with the total asset scale of 671 million yuan. The best fund return during his tenure is -3.58%, while the worst is -17.61% [2]

Core Viewpoint - As of September 3, a total of 129 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more, indicating strong investor interest in these stocks [1] Group 1: Stocks with Longest Net Inflows - The stocks with the longest consecutive net inflows are Meishuo Technology and China Steel International, both having recorded net inflows for 16 consecutive trading days [1] - Other stocks with significant consecutive net inflows include Yanjinpuzi, Sanwei Co., Eastern Airlines Logistics, Lante Optics, Lude Environment, Hualan Biological Engineering, Yunnan Energy Investment, and Information Development [1]

Core Viewpoint - The announcement details the completion and results of a share reduction plan by a major shareholder, Ruizhong Life Insurance Co., Ltd., which reduced its stake in Jiangsu Hualan Pharmaceutical Materials Co., Ltd. by 1.00% through a series of transactions [1][2]. Summary by Sections Shareholder Reduction Plan - Ruizhong Life Insurance planned to reduce its holdings by up to 1,263,089 shares (1.00% of total shares) through centralized bidding and up to 2,526,178 shares (2.00% of total shares) via block trading within a specified period [1]. - The actual reduction amounted to 1,263,000 shares, representing 0.7692% of the total share capital, with an average price range of 30.08 to 31.92 yuan per share [1]. Shareholding Changes - Prior to the reduction, Ruizhong Life held 21,956,522 shares (17.38% of total shares), which decreased to 21,459,922 shares (16.99% of total shares) post-reduction [1]. - After the company's capital increase and distribution of dividends, Ruizhong Life's holdings increased to 26,901,579 shares, reflecting a change in ownership percentage [2]. Compliance and Commitments - Ruizhong Life has adhered to its commitments regarding shareholding and reduction intentions, ensuring no violations of relevant regulations or agreements [3][4]. - The company confirmed that all shares held were free from any pledges or disputes, and it has complied with the lock-up period and reduction procedures as stipulated [3][4].